Compare Entegris Inc (ENTG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Sanofi SA — how do they compare? Entegris Inc trades at $165 (market cap $24.78B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 3.8× Entegris Inc's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Sanofi SA for 94 Days on average.
| ENTG | SNY | |
|---|---|---|
Market Cap | $24.78B | $95.18B |
Volume | 2,648,320 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $184.00 | $52.34 |
52-Week Low | $68.80 | $39.51 |
Typical Hold Time | 41 Days | 94 Days |
Enterprise Value | $27.99B | $114.48B |
Dividend Yield | 0.25% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Entegris (ENTG) trades at $165.79, down 0.32% on the day, with strong technical momentum as the stock approaches resistance at $166. The company demonstrates solid fundamentals with Q2 2026 EPS of $0.93 beating expectations by 13%, driven by AI-related semiconductor demand. Revenue remains stable at $3.2B with improving net margins of 9.18%. Recent news highlights institutional accumulation and patent defense successes.
Outlook remains positive with 70% analyst buy ratings and $182.43 consensus target suggesting 10% upside. Key catalysts include Q3 earnings on October 29 and Investor Day on November 9. Risks include elevated valuation multiples (P/E 81.1) and semiconductor cycle sensitivity. The stock offers growth exposure to advanced semiconductor materials with institutional confidence.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
